Protalix Biotherapeutics (PLX) 4.15 $PLX
Protalix BioTherapeutics Up 5.1%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Tue Mar 25, 12:45PM CDT
Protalix BioTherapeutics (AMEX

LX) is one of today's best performing low-priced stocks, up 5.1% to $4.76 on 1.1x average daily volume. Protalix BioTherapeutics has traded 246,000 shares thus far today, vs. average volume of 232,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.7%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading.
Uptrend Call Working As Protalix BioTherapeutics Stock Rises 9.4% (PLX)
Comtex SmarTrend(R) - Fri Mar 07, 11:24AM CST
SmarTrend identified an Uptrend for Protalix BioTherapeutics (AMEX

LX) on February 10th, 2014 at $4.67. In approximately 4 weeks, Protalix BioTherapeutics has returned 9.40% as of today's recent price of $5.10.
Godliness and Hard Work
by Adam Hartman - All Africa Global Media - Thu Feb 13, 6:11AM CST
OTJIMBINGWE'S Da-Palm Senior Secondary School's recipe for producing best Grade 12 results is simple - Godliness and hard work - according to the principal.
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebrosidase (GCD), and contains the same active substance as taliglucerase alfa (ELELYSO(TM)), the Company's approved enzyme replacement therapy.
Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property
GlobeNewswire - Thu Feb 06, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), announced today that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundacão Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO(TM) (alfataliglicerase). The Company announced the execution of the supply and technology transfer agreement on June 19, 2013, and receipt of the approval results in the final effectiveness of the agreement as of January 23, 2014. The Company has already completed the first shipment of the drug to Brazil under the agreement.
IHG Opens Crowne Plaza Hotel Near JFK International Airport
M2 - Fri Jan 31, 12:02PM CST
InterContinental Hotels Group has expanded its portfolio of New York hotels with the opening of the Crowne Plaza JFK Airport New York City hotel.
Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada
GlobeNewswire - Thu Jan 23, 3:30PM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), announced today that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease. The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations and, upon completion of the evaluation, Health Canada recommended approval from a facility perspective. A decision on final marketing approval of taliglucerase alfa in Canada is expected during 2014.
3 High-Risk, High-Reward Biotech Stocks for Long Term Investors
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jan 22, 4:02PM CST
Investors love being early adopters and supporters of innovative and disruptive companies, especially biotech companies, which can yield outsized gains. Unfortunately, it can be difficult to decipher which developmental companies truly have an edge,...
2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
Hot Stock: Protalix BioTherapeutics, Shares Gain 7.3% (PLX)
Comtex SmarTrend(R) - Mon Jan 13, 10:14AM CST
Protalix BioTherapeutics (AMEX

LX) is one of today's best performing low-priced stocks, up 7.3% to $4.85 on 1.2x average daily volume. Thus far today, Protalix BioTherapeutics has traded 343,000 shares, vs. average volume of 284,000 shares per day. The stock has outperformed the Dow (7.3% to the Dow's -0.0%) and outperformed the S&P 500 (7.3% to the S&P's -0.0%) during today's trading.
Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
GlobeNewswire - Mon Jan 13, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will discuss the Company's corporate objectives and key milestones in a presentation at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. Dr. Aviezer's presentation will include a discussion of the Company's 2014 strategic outlook and clinical highlights. A live webcast of the presentation will be available at www.protalix.com on the event calendar page, and will be archived for 90 days.
Traders Get Bullish on Shares of Protalix BioTherapeutics, Shares Up 8.4% (PLX)
Comtex SmarTrend(R) - Wed Jan 08, 11:42AM CST
Protalix BioTherapeutics (AMEX

LX) is one of today's best performing low-priced stocks, up 8.4% to $4.41 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 306,000 shares, vs. average volume of 292,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's -0.4%) and outperformed the S&P 500 (8.4% to the S&P's -0.0%) during today's trading.
Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 07, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 13-16, 2014. A live webcast of the presentation will be available at www.protalix.com on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 90 days.
Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 26, 7:11AM CST
Idenix Pharmaceuticals (IDIX) was a big mover last session, as the company saw its shares jump over 18% on the day.
Protalix BioTherapeutics Inc. Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 27, 5:16AM CST
Protalix BioTherapeutics Inc. Enters Oversold Territory
Protalix BioTherapeutics Down 7.3%, Shares Slide into the Red (PLX)
Comtex SmarTrend(R) - Mon Nov 25, 10:29AM CST
Protalix BioTherapeutics (AMEX

LX) is one of today's worst performing low-priced stocks, down 7.3% to $3.96 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 226,000 shares, vs. average volume of 216,000 shares per day. The stock has underperformed the Dow (-7.3% to the Dow's 0.2%) and underperformed the S&P 500 (-7.3% to the S&P's 0.0%) during today's trading.
Will Omnivision (OVTI) Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 25, 8:00AM CST
Omnivision Technology is set to report second-quarter fiscal 2014 results on Nov 25.
The Simplest Biotech Growth Portfolio Ever
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Nov 18, 5:06PM CST
The eye-popping booms of the biotech industry attract many investors, while the demoralizing busts scare plenty more away. It can be a daunting task to identify a biotech company with the potential to successfully commercialize a revolutionary...
Maxim Prices Senior Notes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 12:20PM CST
Maxim Integrated Products, Inc. has recently announced the pricing of senior unsecured notes aggregating $500 million.
Is This Orphan Drugmaker in Trouble?
Leo Sun, The Motley Fool - Motley Fool - Mon Nov 11, 1:30PM CST
Protalix BioTherapeutics , an Israeli company focused on the treatment of Gaucher disease and other rare diseases, recently reported its third-quarter earnings. But its core business -- a joint venture with Pfizer to sell its Gaucher disease drug...